β-Blockers in hypertension - The emperor has no clothes: An open letter to present and prospective drafters of new guidelines for the treatment of hypertension

American Journal of Hypertension

Volumn 16, Issue 10, 2003, Pages 870-873

  Messerli, Franz H ^a   Beevers, D Gareth ^b   Franklin, Stanley S ^c   Pickering, Thomas G ^d  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Adverse effects; Beta blockers; Heart attack; Inefficacy; Stroke

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LOSARTAN; THIAZIDE DIURETIC AGENT;

BETA ADRENERGIC RECEPTOR BLOCKING; CEREBROVASCULAR DISEASE; CLINICAL PATHWAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; DIABETIC HYPERTENSION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; EXHAUSTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LETHARGY; ORGANIC IMPOTENCE; PEAK EXPIRATORY FLOW; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SLEEP DISORDER;

EID: 0141786711     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(03)01017-3     Document Type: Article

References (35)

1. Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
2. Ramsay LE, Williams B, Johnson GD, MacGregor GA, Poston L, Potter JF, Poulter NR, Russell G: British Hypertension Society Guidelines for Hypertension Management 1999; Summary. BMJ 1999;319:630-635.
3. Medical Research Council Working Party: MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.
4. MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.
5. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, Hornkvist PE, Pennert K, Tuomilehto J, Wedel H: Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-572.
6. Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Barber HJ, Eliasson K, Elmfeldt D, Jastrup B, Karatzas NB, Leer J, Marchetta F, Ragnarsson J, Robitaille N-M, Valkova L, Wesseling H, Berglund G: Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 1991;17:579-588.
7. Staessen J, Fagard R, Amery A: Primary prevention with metoprolol in patients with hypertension. JAMA 1988;260:1713-1714.
8. Kaplan NM: Critical comments on recent literature. SCRAAPHY about MAPHY from HAPPHY. Am J Hypertens 1988;1:428-430.
9. Dahlof B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester P-O: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-1285.
10. Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986;293:1145-1151.
11. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lamaitre RN, Wagner EH, Furberg CD: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-745.
12. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-2544.
13. IPPPSH Collaborative Group: Cardiovascular risk and risk factors in a randomized trial of treatment based on the β-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985;3:379-392.
14. Eriksson S, Olofsson B-O, Wester P-O, for the TEST study group: Atenolol in secondary prevention after stroke. Cerebrovasc Dis 1995;5:21-25.
15. Dutch TIA Trial Study Group: Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993;24:543-548.
16. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
17. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
18. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Leberballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-1498.
19. Messerli FH, Grossman E, Goldbourt U: Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998;279:1903-1907.
20. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
21. Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J: Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Am J Hypertens 1995;8:1147-1153.
22. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-anatysis of randomized double-blind studies. JAMA 1996;275:1507-1513.
23. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-46.
24. Schiffrin EL, Pu Q, Park JB: Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am J Hypertens 2002;15:105-110.
25. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-1659.
26. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC: Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001;37:250-254.
27. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-912.
28. Messerli FH, Grossman E. Beta-blocker therapy and depression (letter). JAMA 2002;288:1845-1846.
29. Dargie HJ: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390.
30. Viscoli CM, Horwitz RI, Singer BH: Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med 1993;118:99-105.
31. Gheorghiade M, Colucci WS, Swedberg K: Beta-blockers in chronic heart failure. Circulation 2003;107:1570-1575.
32. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003;289:2560-2571.
33. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A, Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
34. Beevers DG: Beta-blockers for hypertension: time to call a halt. J Hum Hypertens 1998;12:807-810.
35. Andersen HC. The emperor's new clothes. In Fairy Tales and Stories, vol. 3, 1837.